These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 25706700)
41. Role of mycophenolate mofetil in remission maintenance after a successful response to rituximab. Sharma AP; Filler G Pediatr Nephrol; 2009 Feb; 24(2):423-4. PubMed ID: 18853197 [No Abstract] [Full Text] [Related]
42. Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy. Yang T; Nast CC; Vo A; Jordan SC Nephrol Dial Transplant; 2008 Jan; 23(1):377-80. PubMed ID: 17981884 [No Abstract] [Full Text] [Related]
43. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Benz K; Dötsch J; Rascher W; Stachel D Pediatr Nephrol; 2004 Jul; 19(7):794-7. PubMed ID: 15071769 [TBL] [Abstract][Full Text] [Related]
44. Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Sellier-Leclerc AL; Macher MA; Loirat C; Guérin V; Watier H; Peuchmaur M; Baudouin V; Deschênes G Pediatr Nephrol; 2010 Jun; 25(6):1109-15. PubMed ID: 20238230 [TBL] [Abstract][Full Text] [Related]
45. Effect of rituximab in MCNS: a role for IL-13 suppression? Kim JE; Park SJ; Ha TS; Shin JI Nat Rev Nephrol; 2013 Sep; 9(9):551. PubMed ID: 23958716 [No Abstract] [Full Text] [Related]
46. Results of immunodepressive treatment in the nephrotic syndrome. Pachiolo R; Genova R Helv Paediatr Acta; 1970 Jan; 25(1):50-8. PubMed ID: 5438807 [No Abstract] [Full Text] [Related]
47. Steroid-sensitive nephrotic syndrome: an evidence-based update of immunosuppressive treatment in children. Larkins N; Kim S; Craig J; Hodson E Arch Dis Child; 2016 Apr; 101(4):404-8. PubMed ID: 26289063 [TBL] [Abstract][Full Text] [Related]
55. Should cyclosporine replace cytoxan or chlorambucil as the second-line drug for steroid-dependent nephrotic syndrome? Brouhard BH Semin Nephrol; 1998 May; 18(3):367-9. PubMed ID: 9613881 [No Abstract] [Full Text] [Related]
56. New insights into treatment of nephrotic syndrome in children. Wang X; Xu H Contrib Nephrol; 2013; 181():119-30. PubMed ID: 23689574 [TBL] [Abstract][Full Text] [Related]
57. Rituximab-responsive nephrotic syndrome due to minimal change disease in systemic lupus erythematosus. Shahane A; Khasnis A; Gota C J Clin Rheumatol; 2012 Jun; 18(4):199-202. PubMed ID: 22647855 [No Abstract] [Full Text] [Related]
58. [Tacrolimus: secondary or main player in children with steroid-resistant nephrotic syndrome?]. Semeraro L G Ital Nefrol; 2012; 29(6):649. PubMed ID: 23229661 [No Abstract] [Full Text] [Related]
59. Rituximab treatment for recurrence of nephrotic syndrome in a pediatric patient after renal transplantation for congenital nephrotic syndrome of Finnish type. Chaudhuri A; Kambham N; Sutherland S; Grimm P; Alexander S; Concepcion W; Sarwal M; Wong C Pediatr Transplant; 2012 Aug; 16(5):E183-7. PubMed ID: 21672106 [TBL] [Abstract][Full Text] [Related]
60. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Ntatsaki E; Carruthers D; Chakravarty K; D'Cruz D; Harper L; Jayne D; Luqmani R; Mills J; Mooney J; Venning M; Watts RA; Rheumatology (Oxford); 2014 Dec; 53(12):2306-9. PubMed ID: 24729399 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]